Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) has a beta value of -4.5 and has seen 2,627,096 shares traded in the last trading session. The company, currently valued at $538.79 Million, closed the last trade at $14 per share which meant it lost -$3.01 on the day or -17.7% during that session. The NLTX stock price is -29.5% off its 52-week high price of $18.13 and 83.57% above the 52-week low of $2.3. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.34 Million shares traded. The 3-month trading volume is 414.25 Million shares.

The consensus among analysts is that Neoleukin Therapeutics, Inc. (NLTX) is a Buy stock at the moment, with a recommendation rating of 1.5. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 6 have rated it as a Hold, with 6 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.22.

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) trade information

Despite being -17.7% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Jul 01 when the NLTX stock price touched $17.39- or saw a rise of 19.49%. Year-to-date, Neoleukin Therapeutics, Inc. shares have moved 13.64%, while the 5-day performance has seen it change -17.74%. Over the past 30 days, the shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) have changed 5.34%. Short interest in the company has seen 2.33 Million shares shorted with days to cover at 0.01.

Wall Street analysts have a consensus price target for the stock at $22, which means that the shares’ value could jump 57.14% from current levels. The projected low price target is $20 while the price target rests at a high of $28. In that case, then, we find that the current price level is +100% off the targeted high while a plunge would see the stock lose 42.86% from current levels.

Neoleukin Therapeutics, Inc. (NLTX) estimates and forecasts

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +1.3% over the past 5 years. Earnings growth for 2020 is a modest -91.3% while over the next 5 years, the company’s earnings are expected to increase by 26.5%.